Getinge plans to leave surgical perfusion
Getinge plans to phase out its surgical perfusion business in a move expected to benefit major players such as LivaNova, ...
Q4 2024 AVITA Medical Inc Earnings Call
Welcome to the AVITA Medical fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference ...
Healio2d
Program improves surgical outcomes, preserves independence for older adults with cancer
An American College of Surgeons initiative reduced postoperative hospitalization among older adults with cancer, according to ...
Healthful News: Baptist Health, Community Hospice break ground for new facilities
Baptist's new HealthPlace at Seven Pines, Community Hospice's pediatric center and UF Health corporate restructure among ...
Winston-Salem Journal2d
SHP board moves forward on considering premium increases for state government employees
The State Health Plan's Board of Trustees authorized staff to flesh out a proposal that would base the percentage increase of ...
Trump announces reciprocal tariffs plan; India’s Modi visits White House to talk AI, energy, defense: Live
Trump announces reciprocal tariffs and doubles down on Canadian statehood at Oval Office press conference: Live - Meanwhile, ...
Biodexa Pharmaceuticals PLC: Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...
Le Lézard2d
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...